New Inhibitors for Prostate Cancer Treatment
Author Information
Author(s): Grigoryev D N, Long B J, Nnane I P, Njar V C O, Liu Y, Brodie A M H
Primary Institution: Department of Pharmacology and Experimental Therapeutics, University of Maryland, School of Medicine
Hypothesis
The study aims to evaluate the effectiveness of new 17α-hydroxylase/C17,20-lyase inhibitors in treating prostate cancer.
Conclusion
The new inhibitors VN/85-1 and VN/87-1 show promise as potential treatments for prostate cancer by effectively inhibiting tumor growth.
Supporting Evidence
- VN/85-1 and VN/108-1 had the lowest IC50 values of 1.25 nM and 2.96 nM respectively.
- The Δ5NCIs decreased the proliferation of LNCaP cells by 35–40%.
- All of the Δ4NCIs stimulated LNCaP cells growth 1.5- to 2-fold.
- VN/85-1 was as effective as finasteride at inhibiting tumor growth.
- The inhibitory effect of VN/87-1 was similar to that of castration.
Takeaway
Scientists created new medicines to help fight prostate cancer, and they found some that work really well in tests.
Methodology
The study involved testing new azolyl steroids on LNCaP prostate cancer cells and in male SCID mice with tumor xenografts.
Participant Demographics
Male severe combined immunodeficient mice were used in the study.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website